These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 12538644

  • 1. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.
    Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.
    J Biol Chem; 2003 Mar 28; 278(13):11032-40. PubMed ID: 12538644
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
    J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
    Pereira T, Zheng X, Ruas JL, Tanimoto K, Poellinger L.
    J Biol Chem; 2003 Feb 28; 278(9):6816-23. PubMed ID: 12468553
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 11. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 Nov 16; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 12. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 13. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.
    Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493
    [Abstract] [Full Text] [Related]

  • 14. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha.
    Yuan Y, Hilliard G, Ferguson T, Millhorn DE.
    J Biol Chem; 2003 May 02; 278(18):15911-6. PubMed ID: 12606543
    [Abstract] [Full Text] [Related]

  • 15. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.
    Science; 2001 Apr 20; 292(5516):468-72. PubMed ID: 11292861
    [Abstract] [Full Text] [Related]

  • 16. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
    Kim W, Kaelin WG.
    Curr Opin Genet Dev; 2003 Feb 20; 13(1):55-60. PubMed ID: 12573436
    [Abstract] [Full Text] [Related]

  • 17. Regulation of the HIF pathway: enzymatic hydroxylation of a conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex.
    Mole DR, Pugh CW, Ratcliffe PJ, Maxwell PH.
    Adv Enzyme Regul; 2002 Feb 20; 42():333-47. PubMed ID: 12123724
    [No Abstract] [Full Text] [Related]

  • 18. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
    Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY.
    Nature; 2002 Jun 27; 417(6892):975-8. PubMed ID: 12050673
    [Abstract] [Full Text] [Related]

  • 19. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
    Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI.
    J Biol Chem; 2001 May 04; 276(18):15306-15. PubMed ID: 11278694
    [Abstract] [Full Text] [Related]

  • 20. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ.
    Mol Cell Biol; 2002 Mar 04; 22(6):1947-60. PubMed ID: 11865071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.